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ABSTRACT 
Background: Currently, one of the most common causes of hospitalization, especially in the elderly, 
is heart failure (HF) exacerbation. In nearly 95% of patients, this is caused by fluid overload. There 
have been studies comparing the rates of comorbidities and biochemical disturbances in HF patients; 
however, their hemodynamic parameters have not yet been assessed. Thus, the aim of this study 
was to compare the clinical presentations and hemodynamic parameters assessed via impedance 
cardiography (ICG) in patients hospitalized due to acute HF, stratified by the left-ventricular ejection 
fraction (LVEF).
Methods: This study enrolled 102 patients, aged > 18 years, hospitalized due to decompensated HF. 
Ninety-seven patients (74 men, 23 women) underwent echocardiographic examination. Biochemical 
and hemodynamic parameters were assessed on the day of admission and, subsequently, every 
other day during hospitalization. Based on echocardiographic findings and the ESC guidelines the 
study group was divided into the following subgroups: HFrEF (EF < 40%), HFpEF (EF > 50%), and 
HFmrEF (EF 40–49%).
Results: The HFrEF group, which constituted 60.8% of patients (n = 58), was predominantly male (P = 
0.0005); and most had elevated N-terminal pro-brain natriuretic peptide levels (P = 0.0008). The HFpEF and 
HFmrEF subgroups, jointly (n = 38), were characterized by higher systolic blood pressure (P = 0.0001), 
and lower hemoglobin levels (P = 0.003). The hemodynamic assessment showed that HFrEF patients 
had higher total fluid content (P = 0.005) and lower systolic time ratio (P = 0.0002).
Conclusions: Despite similar clinical presentation, patients with HF exhibited different values of hemody-
namic and biochemical parameters depending on their LVEF; this indicates non-homogeneity of patho-
mechanisms and causes of HF decompensation.
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Introduction
Diagnostics and treatment of acute heart failure 
(AHF) are one of the key problems in intensive cardiac 
care [1]. The prognosis remains poor, with in-hospital 
mortality of 4.1–13.9% [2–6]. The current European 
Society of Cardiology (ESC) guidelines emphasize the 
need for urgent AHF management [2, 7]. In order to be 
effective, management should be based on detailed 
clinical assessment, aiming to identify the key mecha-
nism of cardiovascular decompensation [8]. Whereas 
most patients with heart failure (HF) and left-ventricular 
ejection fraction (LVEF) < 40% (i.e. HF with reduced 
ejection fraction, HFrEF) exhibit evidence of fluid ac-
cumulation and fluid redistribution to the lungs, which 
leads to pulmonary congestion, those with HF with mid-
range (mildly reduced) ejection fraction (HFmrEF) and 
HF with preserved ejection fraction (HFpEF) typically 
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show more diverse pathomechanisms [9–13]. The latter 
two subgroups (HFmrEF and HFpEF) constitute an 
increasing proportion of patients with AHF [14,15,16]. 
These patients are typically elderly, often with concom-
itant diabetes mellitus, hypertension, atrial fibrillation, 
and/or obesity [17, 18]. Their treatment may, therefore, 
present more challenges, as recommendations for their 
management are based mainly on expert opinions.
Thus, it is useful to search for diagnostic methods 
that would provide additional data compared to that ob-
tained from routine assessments, while at the same time 
being simple enough to be used in intensive-care set-
tings. These conditions seem to be met by impedance 
cardiography (ICG), a simple, non-invasive method of 
assessing the hemodynamic parameters that reflect the 
cardiac function as a pump (including cardiac index 
(CI), stroke index (SI), systemic vascular resistance 
index (SVRI)) and thoracic fluid content (TFC) [19].
Therefore, the aim of this study was to compare 
clinical presentations between subgroups of patients 
hospitalized for AHF stratified by LVEF, with a particular 
emphasis on their hemodynamic profiles.
Methods
This prospective, observational study enrolled pa-
tients of both sexes, aged > 18 years, who were admitted 
to the Department of Cardiology and Internal Diseases 
due to decompensated HF (defined based on ESC 
guidelines) in the period between November 2014 and 
March 2017 and required intravenous diuretic treatment.
Exclusion criteria were: 1) unstable angina; 2) 
history of acute coronary syndrome (ACS) within the 
last 12 weeks and/or coronary artery bypass grafting 
(CABG) surgery within the last 12 weeks; 3) cardiac 
resynchronization therapy (CRT) introduced within the 
last year (or planned CRT implantation within the next 
24 months); 4) non-cardiogenic shock; 5) valvular dis-
ease or other acquired heart defects requiring surgical 
intervention; 6) hypertrophic cardiomyopathy; 7) severe 
pulmonary hypertension or other severe lung condition 
(severe form of chronic obstructive pulmonary disease 
(COPD) or bronchial asthma); 8) poorly controlled 
hypertension; 9) anaemia (haemoglobin < 10.0 g/dL); 
10) acute and/or decompensated non-cardiovascular 
disease; 11) end-stage CKD and/or ongoing hemo-
dialysis therapy; 12) severe or chronic inflammatory 
disease, severe infection (including febrile conditions, 
radiologically-confirmed pneumonia, suspected septic 
shock); 13) neoplastic disease; 14) severe psychiatric 
disorder; 15) the lack of informed consent.
The study protocol was approved by the Military In-
stitute of Medicine Institutional Review Board (approval 
No. 14/WIM/2012), and all study participants provided 
their written informed consent. This study was registered 
at ClinicalTrials.gov (NCT 02355769).
Clinical examinations were conducted with a partic-
ular emphasis on the history of symptoms, concomitant 
diseases, and current medication. The following were 
measured on physical examination: heart rate (HR), 
office systolic blood pressure (SBP), office diastolic 
blood pressure (DBP), and basic body parameters.
Laboratory tests were conducted on fasting periph-
eral venous blood samples, collected in the morning 
(7:30–8:30 a.m.). The following hematological and 
biochemical parameters were measured: hematocrit, 
as well as hemoglobin, urea, creatinine, N-terminal 
pro-brain natriuretic peptide (NTproBNP), high-sensi-
tivity troponin T (hsTnT) levels. The estimated glomer-
ular filtration rate (eGFR) was estimated based on the 
Modification of Diet in Renal Disease (MDRD) study 
equation [20].
Echocardiographic examinations were conduct-
ed with Vivid S6 (GE-Healthcare, USA) and Vivid 
7 (GE-Healthcare, USA) ultrasound systems and eval-
uated cardiac chamber dimensions, left ventricular 
wall thickness and contractility, ejection fraction with 
the biplane  Simpson’s method, as well as valvular 
structure and function. Echocardiography reports in-
cluded any moderate-to-severe mitral, tricuspid, and/or 
aortic regurgitation; severe aortic stenosis; as well as 
the numerical values of the following parameters: left 
ventricular end-diastolic diameter (LVEDD), right ven-
tricular end-diastolic diameter (RVEDD), interventricular 
septum (IVS), left atrial (LA) diameter, measured in the 
parasternal long-axis view.
Impedance cardiography (ICG). All ICG measure-
ments were performed with the Niccomo™ device 
(Medis, Germany) within 24 hours of admission, after 
10 minutes of rest in a sitting position. Data was re-
corded during a 10-minute assessment and exported 
to the dedicated software (Niccomo Software). The 
final analysis included mean values of hemodynamic 
parameters, such as: TFC [1/kOhm], calculated from 
basic impedance (Z0) as its reciprocal: TFC = 1000/Z0; 
SI, calculated using the Sramek and Bernstein formula 
for stroke volume (SV) = VEPT×dZmax×LVET/Z0 and 
indexed to body surface area to yield SI [mL/m2]; CI 
[(mL/min)/m2], calculated as SI×HR; acceleration 
index (ACI [1/100*Ohm/s2]), expressing the maximum 
acceleration of blood in the aorta from the moment the 
aortic valve opens; velocity index (VI [1/1000*Ohm/s] 
expressing the maximum velocity of blood in the aorta 
from the moment the aortic valve opens; Heather index 
(HI [Ohm*s2]), characterizing the maximum contraction 
force of the left ventricle, corresponding to cardiac 
inotropism; SVRI [(dyn×s)/cm5/m2)], calculated as 
80×(MBP–CVP)/CI, where CVP is central venous pres-
sure (with an assumed value of 6 mm Hg).
Agata Galas et al., What distinguishes the patients with low ejection fraction from among those hospitalized for decompensated heart failure?
197www.journals.viamedica.pl/medical_research_journal
Figure 1. Analysis assumptions — compared subgroups (HFrEF — heart failure with reduced left ventricular ejection 
fraction; HRmrEF — heart failure with mid-range left ventricular ejection fraction; HFpEF — heart failure with preserved 
left ventricular ejection fraction, LVEF — left ventricular ejection fraction)
Statistical analysis. The statistical analysis of data 
was conducted with the use of MS Office Excel 2013 and 
Statistica 12.0 (StatSoft Inc.). Data distribution was 
presented on histograms and evaluated visually. The 
results for qualitative variables were expressed as 
numbers and percentages; while continuous (quanti-
tative) variables were expressed as means ± standard 
deviation (SD). For a comparative analysis, the study 
group was divided into two subgroups: patients with 
LVEF < 40% (n = 59) and LVEF ≥40% (n = 38) (Fig-
ure 1).
Results
Clinical characteristics
The subgroup with LVEF < 40% comprised predom-
inantly men with ischemic HF etiology. These patients 
were younger than those in the LVEF ≥ 40% subgroup 
(Table 1). Nonetheless, the two groups showed no 
significant differences in terms of the New York Heart 
Association (NYHA) functional class, rates of dyspnea, 
or a history of edema, or pathological weight gain. Phys-
ical examination of patients with higher LVEF showed 
higher blood pressure values, higher rates of peripheral 
edema, and lower rates of peripheral hypoperfusion. 
The subgroups differed only slightly in terms of medica-
tion, with higher rates of angiotensin-converting enzyme 
(ACE) inhibitors in the LVEF ≥ 40% subgroup.
The echocardiographic examination showed 
the mean LVEF value in the study population of 
37.3 ± 14.1%, LVEDD of 59.2 ± 10.2 mm, RVEDD of 
35.3 ± 5.7 mm, and LA dimeter of 47.3 ± 0.60 mm. 
In comparison, patients with LVEF < 40% had larger 
cardiac chamber dimensions, higher rates of mod-
erate/severe mitral regurgitation, with lower rates of 
moderate/severe aortic stenosis (Table 2).
The mean NT-proBNP level in the LVEF < 40% 
subgroup was significantly higher than that in the sub-
group with better LVEF (Table 3). There was a significant 
correlation between LVEF values and NT-proBNP levels 
(R = -0.38; P < 0.0001). At the same time, patients with 
LVEF ≥ 40% had significantly lower hemoglobin levels 
and hematocrit values, with comparable markers of 
renal function.
The two compared subgroups differed significant-
ly in terms of hemodynamic profiles. Patients with 
LVEF < 40% exhibited lower SBP values, lower values 
of cardiac function as a pump (SI, CI, HI, ACI, VI), higher 
TFC, and a less favourable ratio of pre-ejection period 
(PEP) to left ventricular ejection time (LVET) (Table 4, 
Fig. 2). These differences were confirmed when we 
assessed the correlation of these parameters with LVEF.
Discussion
our findings demonstrated that the clinical presen-
tation of decompensated HFrEF differs from that of 
HFmrEF/HFpEF. Our observations regarding age differ-
ences, sex distribution, HF etiology, echocardiographic 
findings, and comorbidities are essentially consistent 
with those presented in earlier reports. Impedance car-
diography proved to significantly differentiate patients 
from the two evaluated subgroups. Patients with higher 
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Table 1. The comparison between patients with LVEF < 40% and LVEF ≥ 40% — patients characteristics
LVEF < 40%
N = 59
LVEF ≥ 40%
N = 38
P Whole group
N = 97
n (%)/ mean ± SD
Age, mean ± SD 68.1 ± 13.2 76.7 ± 9.5 0.0005 71.5 ± 12.6
Male, mean ± SD 50 (84.8) 24 (63.2) 0.015 74 (76.3)
NYHA class
Mean class NYHA [-], mean ± SD 3.32 ± 0.57 3.32 ± 0.52 0.897 3.32 ± 0.55
class III, n (%) 37 (62.7) 25 (65.8) 0.773 62 (63.9)
class IV, n (%) 22 (67.3) 13 (34.2) 0.773 35 (36.1)
HF de novo, n (%) 16 (27.1) 10 (26.3) 0.931 26 (26.8)
Ischemic etiology, n (%) 41 (69.5) 21 (55.3) 0.003 62 (63.9)
CLINICAL EXAMINATION
Dyspnea at rest, n (%) 26 (44.1) 15 (39.5) 0.655 41 (42.3)
Dyspnea on effort, n (%) 58 (98.3) 38 (100.0) 0.420 96 (99.0)
Orthopnoe, n (%) 45 (77.6) 30 (79.0) 0.875 75 (77.3)
Edema, n (%) 44 (74.6) 31 (81.6) 0.421 75 (77,.3)
Pathological weight gain, n (%) 23 (39.0) 14 (36.8) 0.832 37 (38.1)
PHYSICAL EXAMINATION
HR [bpm], mean ± SD 89.4 ± 25.3 82.3 ± 20.1 0.220 86.6 ± 23.5
SBP [mmHg], mean ± SD 127.3 ± 25.6 147.2 ± 27.0 0.0001 135.1 ± 27.2
DBP [mmHg], mean ± SD 80.2 ± 12.8 83.3 ± 12.8 0.282 81.4 ± 13.5
BMI [m2/kg], mean (SD) 28.9 ± 5.8 31.5 ± 6.9 0.094 29.9 ± 6.3
Hypertension (SBP > 140mmHg, DBP >90mmHg), n (%) 6 (10.2) 19 (50.0) 0.00006 25 (25.8)
Hypotension (SBP < 90mmHg), n (%) 3 (5.1) 2 (5.3) ns 5 (5.2)
Tachypnoe, n (%) 14 (23.7) 6 (15.8) 0.345 20 (20.6)
Rales, n (%) 58 (98.3) 38 (100.0) 0.783 96 (99.0)
Edema, n (%) 40 (67.8) 34 (89.5) 0.014 74 (76.3)
Peripheral hipoperfusion, n (%) 9 (15.3) 1 (2.6) 0.046 10 (10.3)
CONCOMITANT DISEASE
Prior MI, n (%) 32 (54.2) 10 (26.3) 0.007 42 (43.3)
Hypertension, n (%) 34 (57.6) 30 (79.0) 0.031 64 (66.0)
Atrial fibrillation, n (%) 29 (49.2) 22 (57.9) 0.400 51 (52.6)
Moderate-to-severe valvular disease, n (%) 18 (30.5) 15 (39.5) 0.477 33 (34.0)
Procedure: ICD, n (%) 10 (17.0) 0 (0.0) 0.040 10 (10.3)
Procedure: CRT, n (%) 5 (8.5) 1 (2.6) 0.040 6 (6.2)
Diabetes mellitus, n (%) 29 (49.2) 19 (50.0) 0.935 48 (49.5)
COPD, n (%) 10 (17.0) 5 (13.2) 0.614 15 (15.5)
CKD (stadium ≥ 3), n (%) 16 (27.6) 12 (31.6) 0.674 28 (28.9)
MEDICATION USE BEFORE HOSPITALIZATION (available for 95) 
ACE-I, n (%) 30 (52.6) 28 (73.7) 0.039 58 (61.1)
ARB, n (%) 5 (8.8) 5 (13.2) 0.495 10 (10.5)
B blocker, n (%) 41 (71.9) 33 (86.8) 0,086 74 (77.9)
Aldosterone antagonists, n (%) 22 (38.6) 9 (23.7) 0.129 31 (32.6)
Diuretics, n (%) 40 (70.2) 29 (76.3) 0.511 69 (72.6)
Iwabradine, n (%) 0 (0.0) 2 (5.3) 0.080 2 (2.1)
Digoxin, n (%) 3 (5.3) 3 (7.9) 0.605 6 (6.3)
Amiodarone, n (%) 10 (17.5) 3 (7.9) 0.180 13 (13.7)
ACE-I — angiotensin-converting-enzyme inhibitors; ARB — angiotensin II receptor blockers; BMI — body mass índex; CKD — chronic kidney disease; 
COPD — chronic obstructive pulmonary disease; CRT — cardiac resynchronization therapy; DBP — diastolic blood pressure; HR — heart rate; ICD — im-
plantable cardioverter defibrillator; MRA — mineralocorticoid receptor antagonista; NYHA — New York Heart Association; SBP — systolic blood pressure
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Table 2. The comparison between patients with LVEF < 40% and LVEF ≥ 40% — echocardiography
LVEF < 40%
N = 59
LVEF ≥ 40%
n=38
p
n (%)/ mean ± SD
LVEDD [mm], mean ± SD 65.0 ± 8.4 51.4 ± 6.6 0.000001
RVEDD [mm], mean ± SD 36.4 ± 6.2 33.7 ± 4.6 0.081
LA [mm], mean ± SD 48.7 ± 5.2 45.6 ± 6.7 0.015
LVEF [%], mean ± SD 27.7 ± 6.5 52.2 ± 8.3 0.000001
MR85, n (%) 32 (65.3) 14 (38.9) 0.016
AS85, n (%) 2 (4.1) 7 (19.4) 0.023
AR85, n (%) 0 (0.0) 2 (5.6) 0.095
TR85, n (%) 19 (38.8) 15 (41.7) 0.707
Upper index — number of subjects with sufficient valve assessment; AR — aortic regurgitation; AS — aortic stenosis; LA — left atrium; LVEDD 
— left ventricle end-diastolic dimension; RVEDD — right ventricle end-diastolic dimension; LVEF — left ventricle ejection fraction; MR — mitral 
regurgitation; TR — tricuspid regurgitation
Table 3. The comparison between patients with LVEF < 40% and LVEF ≥ 40% — laboratory data on admission
LVEF < 40%
N = 59
LVEF ≥ 40%
N = 38
p Whole group
N = 97
mean ± SD
Creatinine [mg/dl], mean ± SD 1.36 ± 0.49 1.24 ± 0.55 0.148 1.31 ± 0.51
eGFR MDRD [ml/min/1.73 m2], mean ± SD 61.5 ± 24.2 63.2 ± 23.0 0.644 62.2 ± 23.6
Urea [mg/dl], mean ± SD 55.8 ± 29.4 51.6 ± 21.6 0.615 54.2 ± 26.6
NT-proBNP [pg/ml], mean ± SD 7991 ± 8463 3453 ± 3031 0.0008 6213 ± 7195
hsTnT [ng/l], mean ± SD 124.5 ± 292.2 79.2 ± 212.2 0.219 106.9 ± 263.4
Hb [g/dl], mean ± SD 13.1 ± 2.0 11.8 ± 2.4 0.003 12.6 ± 2.3
Hematocrit [%], mean ± SD 39.8 ± 5.7 36.4 ± 6.6 0,003 38.5 ± 6.2
eGFR — estimated glomerular filtration rate; Hgb — hemoglobina; hsTnT — high-sensitive cardiac troponin T; NTproBNP — N-terminal fragment 
of the prohormone brain-type natriuretic peptide
LVEF seemed to have less pronounced abnormalities 
in their hemodynamic profile, with higher values of 
parameters indicating cardiac function as a pump and 
lower TFC. However, it is worth noting that the symp-
toms reported by patients with HFmrEF/HFpEF were not 
any less pronounced than those reported by patients 
with LVEF < 40%.
Although, the whole study group was predominantly 
male, the proportion of men was noticeably lower in the 
HFmrEF/HFpEF subgroup. Data from AHF registries 
show the proportion of women in this subgroup to range 
from 53% to 72.4% [21–24].
The patients from the HFmrEF/HFpEF subgroup 
were older and had higher rates of concomitant chronic 
conditions and lower rates of post-infarct HF etiology 
[21]. Patients with HFrEF are known to have higher 
rates of coronary artery disease, while those with HFpEF 
have higher rates of atrial fibrillation, hypertension, and 
anaemia [6, 17, 18, 25]. Particularly interesting were our 
findings on anaemia, which are consistent with earlier 
reports on higher rates of this condition in HFpEF [26, 
27]. Our findings regarding the rates of chronic kidney 
disease (CKD) being comparable in both subgroups 
were also consistent to those reported in many registries 
[23, 28–31]. However, Bishu et al. [27], who assessed 
renal function based on cystatin C levels, demonstrated 
higher rates of CKD in patients with HFmrEF/HFpEF, 
which was most likely due to the selected diagnostic 
marker, as cystatin C is highly sensitive [32, 33–36]. Quiroz 
et al. made similar observations, finding higher admission 
creatinine levels in patients with LVEF > 50% [21].
In our study, the two subgroups differed the most 
in terms of the rates of hypertension, with as many as 
50% of HFmrEF/HFpEF patients presenting with a blood 
pressure of over 140/90 mmHg. This is consistent with 
earlier reports [6, 27, 37] and may be responsible for the 
higher rates of renin-angiotensin-aldosterone system 
(RAAS) inhibitors in the subgroup with LVEF ≥ 40%, 
although some reports have indicated higher rates of 
calcium-channel blockers and alpha-blockers, rather 
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Table 4. The comparison between patients with LVEF < 40% and LVEF ≥ 40% — impedance cardiography
LVEF < 40%
N = 59
LVEF ≥ 40%
N = 38
p LVEF
vs.
n (%)/ mean ± SD R P
IMPEDANCE CARDIOGRAPHY
HR [bpm], mean ± SD 83.8 ± 22.8 77.7 ± 20.1 0.188 -0.03 0.784
SBP [mmHg], mean ± SD 114.6 ± 16.9 136.1 ± 29.5 0.0002 0.38 0.0001
DBP [mmHg], mean ± SD 73.7 ± 11.5 72.2 ± 12.0 0.418 -0.04 0.718
SI [ml*m-2], mean ± SD 36.0 ± 10.4 44.4 ± 13.7 0.004 0.30 0.005
CI [ml*m-2*min-1], mean ± SD 2.86 ± 078 3.12 ± 0,80 0.208 0.24 0.026
HI [Ω•s-2], mean ± SD 7.82 ± 4.77 12.0 ± 6.75 0,002 0,38 0.0003
ACI [1*100-1*s-2], mean ± SD 59.6 ± 23.3 77.1 ± 39.1 0.051 0.25 0.022
VI [1*1000-1*s-1], mean ± SD 38.2 ± 15.7 48.1 ± 25.5 0.120 0.22 0.047
SVRI [dyn*s*cm-5*m²], mean ± SD 2424 ± 733 2292 ± 802 0.457 -0.17 0.131
TFC [1*kOhm-1], mean ± SD 37.4 ± 8.2 33.7 ± 6.5 0.009 -0.28 0.005
STR [%], mean ± SD 0.54 ± 0.33 0.36 ± 0,13 0.001 -0.38 0.0002
PEP [ms], mean ± SD 137.5 ± 62.1 103.2 ± 34.0 0.003 -0.38 0.0002
LVET [ms], mean ± SD 272.5 ± 47.7 303.1 ± 62.8 0.018 0.18 0.100
SI < 35 ml/m2, n (%) 23 (38.9) 8 (21.1) 0.041 - -
TFC > 35 kOhm, n (%) 34 (57.6) 12 (31.6) 0.012 - -
ACI — acceleration time índex; CI — cardiac índex; DBP — diastolic blood pressure; HI — Heather índex; HR — heart rate; LVET — left ventricu-
lar ejection time; PEP — pre-ejection period; SBP — systolic blood pressure; STR — systolic time ratio; SVRI — systemic vascular resistance 
índex; TFC — thoracic fluid contente; SI — stroke índex; VI — velocity index
Figure 2. The comparison of hemodynamic parameters between patients with LVEF < 40% and LVEF ≥ 40%
than RAAS inhibitors, in patients with HFpEF [24, 27]. 
The lower rates of RAAS inhibitor use in patients with 
HFrEF may have been due to the higher rates of objec-
tive clinical contraindications (e.g. hypotension, renal 
dysfunction, hyperkalemia) in this group.
Our findings demonstrated that, in comparison with 
patients with HFrEF, patients with HFmrEF/HFpEF had 
lower natriuretic peptide levels [38–40], which could 
indicate a lower myocardial load in the latter subgroup. 
However, the fact that the HFmrEF/HFpEF subgroup 
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had higher rates of obesity may have also played 
a role, as low levels of natriuretic peptides may be due 
to increased natriuretic peptide absorption by adipo-
cytes [41] as well as their reduced production as part 
of disrupted hormonal metabolism in the obese [42].
Impedance cardiography assessments revealed 
significant differences in hemodynamic profiles between 
the study subgroups stratified by LVEF. To our knowl-
edge, this is the first report of this kind. Our findings 
demonstrated low LVEF to be reflected by lower ICG 
parameters of cardiac function as a pump (SI, CI, HI, 
ACI, VI). The values of these parameters in the HFrEF 
subgroup were comparable to those presented in ear-
lier reports. Kaszuba et al. demonstrated a relationship 
between the ejection fraction and PEP, LVET, and STR, 
although that particular study included patients with 
no manifestations of HF exacerbation [43]. On the 
other hand, the hemodynamic profile of left ventricular 
function in the HFmrEF/HFpEF subgroup more closely 
resembled that in patients with uncomplicated hyper-
tension. Studies evaluating hemodynamic parameters 
in hypertensive patients showed that even diastolic 
dysfunction alone was reflected in lower values of SI, 
VI, ACI, and HI as well as a higher SVRI [44, 45].
It seemed advisable to compare the subgroups also 
in terms of TFC, a parameter useful in differentiating 
the causes of dyspnea and assessing pulmonary con-
gestion [46, 47]. We found that, although the rates of 
patients with elevated TFC were considerable in both 
subgroups, they were noticeably higher in patients with 
HFrEF (57.6 vs. 31.6%). Only one in three patients with 
HFmrEF exhibited marked pulmonary congestion. This 
indicates that diuretic treatment in this subgroup may 
not always be as effective as expected.
Our findings clearly showed differences between the 
hemodynamic profiles of patients with HFmrEF/HFpEF 
and of those with HFrEF. This suggests that the reported 
symptoms could be due mainly to other, concomitant 
conditions (poorly controlled hypertension, arrhythmia, 
or acute exacerbation of CKD, etc.). An ostensibly 
“better” hemodynamic profile does not exclude a poor 
clinical condition and severe symptoms. Moreover, 
the complexity of potential pathomechanisms makes it 
more difficult to select optimal treatment. Therefore, the 
diagnostic assessments in these patients should help 
select a treatment most suitable for the predominant 
cause of HF exacerbation. 
Our findings may explain why it is so difficult to 
obtain robust scientific evidence for the effectiveness 
of selected medications in treating patients with HFm-
rEF/HFpEF. In such a non-homogeneous group [1, 
48] the use of varied regimens, based on individual 
hemodynamic profiles may be a better management 
strategy. Therefore, ICG may be a practical tool in this 
group of patients, as its usefulness in selecting optimal 
treatments based on the individual hemodynamic dis-
turbances has been already demonstrated in patients 
with hypertension [49, 50]. 
Study limitations
One indisputable limitation of our study is the small 
sample size. The observed differences in hemodynamic 
profiles may have been partly due to the uneven distri-
bution of the sexes between the two subgroups. How-
ever, this fact should not be a significant confounding 
factor, as both subgroups were predominantly male. 
Another significant limitation was the 24-hour window 
allowed for hemodynamic assessment, as the hemo-
dynamic profile may change even within less than an 
hour of initiating effective treatment. On the other hand, 
the varied time of echocardiographic examination was 
less problematic, as the LVEF value during clinical 
stabilization is considered to be the most reliable 
prognostic factor.
Conclusion
This study confirms earlier observations on the dif-
ferences between patients with significantly impaired 
left ventricular systolic function versus those with mildly 
impaired and preserved left the ventricular systolic 
function. Despite the fact that left ventricular function 
does not determine the severity of clinical presentation 
in patients with decompensated HF, the observed dif-
ferences in hemodynamic parameters demonstrated 
a non-homogeneity of the pathomechanisms and 
causes of decompensated HF. These findings prompt 
further studies on the use of ICG in patients hospitalized 
due to HF exacerbation.
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